Atralin Acne Gel Awarded “A+” In Valeant Ad, But FDA Sends Promo To Back Of The Class
This article was originally published in The Pink Sheet Daily
Executive Summary
A clever marketing graphic is dinged because it comes in the context of unjustified superiority claims.
You may also be interested in...
FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf
In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.
Valeant Racks Up FDA Letters Criticizing Its Promotional Materials
FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.
Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.